Search

Iterative reconstruction techniques, such as adaptive statistical iterative reconstruction (ASiR), improve the contrast-to-noise ratio of computed tomography (CT) images; however, underlying anatomical structures may nevertheless hamper detectability of low-contrast areas in clinical situations, despite using such a technique. We therefore conducted a phantom study to investigate the efficacy of ASiR in improving the detectability of low-contrast areas in the presence of brain anatomical structures. We developed dedicated head phantoms simulating hyperacute cerebral infarction and confirmed that their CT numbers were sufficiently reproducible and that observer performance in detecting low-contrast areas using these phantoms more closely resembled that in clinical situations than that using a simple phantom. The efficacy of ASiR in improving low-contrast detectability was evaluated via receiver operating characteristics analysis. The mean area under the curve (AUC) values at ASiR blend rates of 0%, 30%, 60%, and 100% were 0.57, 0.57, 0.59, and 0.59 at 200 mA; 0.83, 0.84, 0.84, and 0.90 at 500 mA; and 0.79, 0.77, 0.76, and 0.79 at 800 mA, respectively. No significant differences were noted in AUC values among ASiR blend rates at any mA setting, suggesting that ASiR does not improve the detectability of subtle low-contrast lesions seen in hyperacute cerebral infarction in clinical situations.

The recently introduced 320-detector row computed tomography (320-row CT) allows very fast volumetric acquisition of the entire heart. Because the total amount of contrast agent required for CT coronary angiography (CTCA) depends directly on the acquisition time, 320-row CTCA would substantially reduce the contrast agent dose. The objective of this retrospective study was to evaluate the feasibility of contrast volume reduction on 320-row CTCA compared with 64-detector row CTCA (64-row CTCA). We retrospectively reviewed consecutive 320- and 64-row CTCA data (16 eligible cases for each; administrated contrast volume, 20-24 ml for the former and 50-65 ml for latter) from a homogeneous patient population (age ≤ 81, body weight ≤ 67 kg, and heart rate ≤ 69 bpm). The two types of CTCA data were compared with respect to the successful rate of adequate intravascular contrast enhancement defined as the number of segments with attenuations of more than 250 HU divided by total number of coronary segments evaluated. Our dataset provided mean intravascular attenuation values of 320 and 404 HU on the 320- and 64-row CTCA, respectively. Although the attenuation values were statistically lower for the 320-row CTCA (P < 0.001), there was no significant difference in the successful rates of adequate intravascular contrast enhancement (rate of 0.98 for each; P > 0.05). We therefore conclude that 320-row CTCA is a feasible method of diagnostic imaging and is superior to 64-row CTCA because it uses less of the contrast medium.

To evaluate the feasibility and efficacy of a biweekly schedule of paclitaxel in advanced or recurrent breast cancer, 18 patients were enrolled in this pilot study. Paclitaxel of 120 mg/m2 was administered over 3 hours, and cycles were repeated every two weeks until disease progression or toxicity precluded further treatment. Patients received a median of 10 infusions with actual dose intensity of 55.9 mg/m2/wk, and median time to progression was 4.8 months. The overall response rate was 33.3%, and one patient achieved stable disease for at least 6 months. The responders included patients who received prior anthracycline and/or docetaxel treatment, and the response rate was consistent regardless of metastatic sites. Myelosuppression was the most common toxicity, and a few patients needed G-CSF support, treatment delay or dose reduction because of grade 3 or 4 neutropenia or leukopenia. Although one patient withdrew from this study because of grade 3 sensory disturbance, this regimen was generally well tolerated. A biweekly schedule of paclitaxel seems to be feasible and effective in patients with advanced or recurrent breast cancer.